172 related articles for article (PubMed ID: 19209136)
1. Updates in anti-HER2 combination therapy.
Burstein H
Clin Adv Hematol Oncol; 2008 Dec; 6(12):873-4. PubMed ID: 19209136
[No Abstract] [Full Text] [Related]
2. [Chemotherapy for breast cancer refractory to anthracycline, taxane or trastuzumab].
Ito Y; Kobayashi K
Gan To Kagaku Ryoho; 2009 May; 36(5):726-9. PubMed ID: 19461171
[TBL] [Abstract][Full Text] [Related]
3. Cardiotoxicities of breast cancer treatment.
Viale PH; Yamamoto DS
Oncology (Williston Park); 2009 Apr; 23(4 Suppl Nurse Ed):19-24. PubMed ID: 19856594
[No Abstract] [Full Text] [Related]
4. Breast cancer: Increasing therapy options for HER2-positive early breast cancer.
Harbeck N
Nat Rev Clin Oncol; 2011 Dec; 9(1):10-2. PubMed ID: 22186934
[No Abstract] [Full Text] [Related]
5. When an interim analysis of randomized trial changes the practice in oncology: the lesson of adjuvant Trastuzumab and the HERA trial.
De Rossi C; Brunello A; Jirillo G; Jirillo A
Immunopharmacol Immunotoxicol; 2009 Mar; 31(1):30-1. PubMed ID: 21054206
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular risk profile of patients with HER2/neu-positive breast cancer treated with anthracycline-taxane-containing adjuvant chemotherapy and/or trastuzumab.
Jones LW; Haykowsky M; Peddle CJ; Joy AA; Pituskin EN; Tkachuk LM; Courneya KS; Slamon DJ; Mackey JR
Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):1026-31. PubMed ID: 17507633
[TBL] [Abstract][Full Text] [Related]
7. [Novel targeting therapy concept for breast cancer treatment].
Toi M
Nihon Yakurigaku Zasshi; 2008 Sep; 132(3):177-9. PubMed ID: 18787301
[No Abstract] [Full Text] [Related]
8. Trastuzumab as the lead monoclonal antibody in advanced breast cancer: choosing which patient and when.
Olver IN
Future Oncol; 2008 Feb; 4(1):125-31. PubMed ID: 18241007
[TBL] [Abstract][Full Text] [Related]
9. Breast cancer (metastatic).
Stebbing J; Glassman R
Clin Evid; 2005 Jun; (13):2197-225. PubMed ID: 16135325
[No Abstract] [Full Text] [Related]
10. The role of adjuvant monoclonal antibody therapy for breast cancer: rationale and new studies.
Perez EA
Curr Oncol Rep; 2001 Nov; 3(6):516-22. PubMed ID: 11595120
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant therapy for HER2 positive breast cancer: are anthracyclines still necessary?
Castrellon AB; Glück S
Clin Adv Hematol Oncol; 2008 Sep; 6(9):666-72. PubMed ID: 18827789
[TBL] [Abstract][Full Text] [Related]
12. Drug evaluation: Bay-59-8862.
Eckstein JW
IDrugs; 2004 Jun; 7(6):575-81. PubMed ID: 15197663
[TBL] [Abstract][Full Text] [Related]
13. A phase II trial of oxaliplatin and trastuzumab in the treatment of HER2-positive metastatic breast cancer.
Yardley DA; Daniel D; Stipanov M; Drosick DR; Mainwaring M; Peyton J; Shastry M; Hainsworth JD
Cancer Invest; 2010 Oct; 28(8):865-71. PubMed ID: 20690802
[TBL] [Abstract][Full Text] [Related]
14. New molecule-targeting therapy with herceptin (trastuzumab), an anti-HER2 (c-erB-2) monoclonal antibody.
Sakamoto G; Mitsuyama S
Breast Cancer; 2000; 7(4):350-7. PubMed ID: 11114864
[No Abstract] [Full Text] [Related]
15. Trastuzumab and beyond: New possibilities for the treatment of HER2-positive breast cancer.
Morris SR; Carey LA
Oncology (Williston Park); 2006 Dec; 20(14):1763-71; discussion 1771-2, 1774-6. PubMed ID: 17263127
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy of trastuzumab alone therapy was compared to trastuzumab plus taxane therapy in patients of advanced and metastatic breast cancers].
Sakurai K; Enomoto K; Kitajima A; Tani M; Amano S
Gan To Kagaku Ryoho; 2007 Nov; 34(12):1911-3. PubMed ID: 18219850
[TBL] [Abstract][Full Text] [Related]
17. New drugs in breast cancer.
Iqbal S; Miller WR
Expert Opin Pharmacother; 2001 Jun; 2(6):975-85. PubMed ID: 11585013
[TBL] [Abstract][Full Text] [Related]
18. Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab.
Yao E; Zhou W; Lee-Hoeflich ST; Truong T; Haverty PM; Eastham-Anderson J; Lewin-Koh N; Gunter B; Belvin M; Murray LJ; Friedman LS; Sliwkowski MX; Hoeflich KP
Clin Cancer Res; 2009 Jun; 15(12):4147-56. PubMed ID: 19509167
[TBL] [Abstract][Full Text] [Related]
19. Can HER2 status predict response to cancer therapy?
Nelson NJ
J Natl Cancer Inst; 2000 Mar; 92(5):366-7. PubMed ID: 10699062
[No Abstract] [Full Text] [Related]
20. [Clinical implications of trastuzumab].
Saeki T; Takashima S
Gan To Kagaku Ryoho; 2003 Aug; 30(8):1094-9. PubMed ID: 12938263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
